![Morten Aleksandr Engel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Morten Aleksandr Engel
Directeur/Membre du Conseil chez
PARATEK PHARMACEUTICALS, INC.
Profil
Morten Aleksandr Engel is currently Director at AFYX Therapeutics AS and Paratek Pharmaceuticals, Inc., and Partner at Novo Planetary Health since 2023.
Former positions include Chief Executive Officer at Benchmark Genetics Norway AS, Asset Director at Novo Holdings A, Director at Servier Symphogen.
A and Xellia Pharmaceuticals ApS, Director at Novo Principal Investments from 2016 to 2018, Vice President at Baxter International, Inc., Principal at McKinsey & Co., Inc., Thomson Scientific & Healthcare, and Pfizer (St. Louis), and Partner at Novo Seeds from 2018 to 2024.
Education includes a doctorate conferred in 1999 and a graduate degree conferred in 1995, both from the Massachusetts Institute of Technology.
Postes actifs de Morten Aleksandr Engel
| Sociétés | Poste | Début |
|---|---|---|
| PARATEK PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | - |
AFYX Therapeutics AS
 AFYX Therapeutics AS Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Directeur/Membre du Conseil | - |
Anciens postes connus de Morten Aleksandr Engel
| Sociétés | Poste | Fin |
|---|---|---|
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds invests in companies located in Europe and the United States. The fund targets companies operating in the fields of life science and healthcare technology sectors. It provides financing for seed and early stage capital requirement. | Private Equity Investor | 31/12/2024 |
Novo Principal Investments
 Novo Principal Investments Investment ManagersFinance Novo Principal invests in public and private companies located across Europe and North America. The firm focuses on companies operating in the fields of healthcare and life science sectors. It provides financing for later stage capital requirements. | Private Equity Investor | 01/02/2018 |
BENCHMARK GENETICS NORWAY AS
 BENCHMARK GENETICS NORWAY AS BiotechnologyHealth Technology Provides breeding and genetics solutions for aquaculture | Directeur Général | - |
Xellia Pharmaceuticals ApS
 Xellia Pharmaceuticals ApS Medical/Nursing ServicesHealth Services Provides anti-infective treatments and other critical care therapies services | Directeur/Membre du Conseil | - |
Symphogen A/S
 Symphogen A/S BiotechnologyHealth Technology Develops antibody therapeutics for the treatment of cancers | Directeur/Membre du Conseil | - |
Formation de Morten Aleksandr Engel
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
93
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Baxter International, Inc.
 Baxter International, Inc. Medical SpecialtiesHealth Technology Produces and supplies medical products, healthcare systems, therapies and pharmaceuticals & provide kidney care services | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Novo Holdings A/S (Denmark)
 Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Finance |
Thomson Scientific & Healthcare
 Thomson Scientific & Healthcare Internet Software/ServicesTechnology Services Provides integrated information solutions to researchers, librarians, physicians, pharmacists and other professionals | Technology Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Pfizer (St. Louis)
 Pfizer (St. Louis) BiotechnologyHealth Technology Provides research services in prescription medicines for humans and animals | Health Technology |
Symphogen A/S
Symphogen A/S BiotechnologyHealth Technology Develops antibody therapeutics for the treatment of cancers | Health Technology |
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds invests in companies located in Europe and the United States. The fund targets companies operating in the fields of life science and healthcare technology sectors. It provides financing for seed and early stage capital requirement. | Finance |
Xellia Pharmaceuticals ApS
Xellia Pharmaceuticals ApS Medical/Nursing ServicesHealth Services Provides anti-infective treatments and other critical care therapies services | Health Services |
Novo Principal Investments
Novo Principal Investments Investment ManagersFinance Novo Principal invests in public and private companies located across Europe and North America. The firm focuses on companies operating in the fields of healthcare and life science sectors. It provides financing for later stage capital requirements. | Finance |
Paratek Pharmaceuticals, Inc.
 Paratek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
AFYX Therapeutics AS
AFYX Therapeutics AS Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
BENCHMARK GENETICS NORWAY AS
BENCHMARK GENETICS NORWAY AS BiotechnologyHealth Technology Provides breeding and genetics solutions for aquaculture | Health Technology |
Choisissez Zonebourse 
